Abstract:Background: Maintenance of the genome is essential for cell survival, and impairment of the DNA damage response is associated with multiple pathologies including cancer and neurological abnormalities. DNA-PKcs is a DNA repair protein and a core component of the classical nonhomologous end-joining pathway, but it also has roles in modulating gene expression and thus, the overall cellular response to DNA damage. Methods: Using cells producing either wild-type (WT) or kinase-inactive (KR) DNA-PKcs, we assessed global alterations in gene expression in the absence or presence of DNA damage. We evaluated differential gene expression in untreated cells and observed differences in genes associated with cellular adhesion, cell cycle regulation, and inflammation-related pathways. Following exposure to etoposide, we compared how KR versus WT cells responded transcriptionally to DNA damage. Results: Downregulated genes were mostly involved in protein, sugar, and nucleic acid biosynthesis pathways in both genotypes, but enriched biological pathways were divergent, again with KR cells manifesting a more robust inflammatory response compared to WT cells. To determine what major transcriptional regulators are controlling the differences in gene expression noted, we used pathway analysis and found that many master regulators of histone modifications, proinflammatory pathways, cell cycle regulation, Wnt/β-catenin signaling, and cellular development and differentiation were impacted by DNA-PKcs status. Finally, we have used qPCR to validate selected genes among the differentially regulated pathways to validate RNA sequence data. Conclusion: Overall, our results indicate that DNA-PKcs, in a kinase-dependent fashion, decreases proinflammatory signaling following genotoxic insult. As multiple DNA-PK kinase inhibitors are in clinical trials as cancer therapeutics utilized in combination with DNA damaging agents, understanding the transcriptional response when DNA-PKcs cannot phosphorylate downstream targets will inform the overall patient response to combined treatment.

Secrets of DNA-PKcs beyond DNA repair

DNA-Dependent Protein Kinase Catalytic Subunit (DNA-PKcs): Beyond the DNA Double-Strand Break Repair

Beyond DNA Repair: DNA-PKcs in Tumor Metastasis, Metabolism and Immunity

Beyond DNA Repair: DNA-PK Function in Cancer

The multifaceted functions of DNA-PKcs: implications for the therapy of human diseases

DNA-PKcs: A Multi-Faceted Player in DNA Damage Response

DNA-PK as an Emerging Therapeutic Target in Cancer

Targeting the DNA Repair Pathway for Breast Cancer Therapy: Beyond the Molecular Subtypes.

In-Depth Mapping of DNA-PKcs Signaling Uncovers Conserved Features of Its Kinase Specificity

In-depth mapping of DNA-PKcs signaling uncovers noncanonical features of its kinase specificity

Development and therapeutic potential of DNA-dependent protein kinase inhibitors

Repair-independent functions of DNA-PKcs protect irradiated cells from mitotic slippage and accelerated senescence

Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010–present)

Role of PRKDC in cancer initiation, progression, and treatment

Comparative analysis of basal and etoposide-induced alterations in gene expression by DNA-PKcs kinase activity

DNA–dependent protein kinase in telomere maintenance and protection

Targeting DNA Repair Pathways: Mechanisms and Potential Applications in Cancer Therapy

PKA prevents resection of DNA double strand breaks and favor non-homologous end-joining

Comparative gene expression in cells competent in or lacking DNA-PKcs kinase activity following etoposide exposure reveal differences in gene expression associated with histone modifications, inflammation, cell cycle regulation, Wnt signaling, and differentiation

Molecular Pathways: Emergence of Protein Kinase CK2 (CSNK2) as a Potential Target to Inhibit Survival and DNA Damage Response and Repair Pathways in Cancer Cells

Catalytic Subunit of DNA-dependent Protein Kinase: Impact on Lymphocyte Development and Tumorigenesis